GSK’s follow-up to its severe asthma therapy Nucala has shown its value in a pair of phase 3 trials, reducing exacerbations compared to placebo with dosing once every six months. The company ...

GSK’s new asthma drug Relvar Ellipta has ... Ellipta treatment had twice the odds of achieving an improvement in asthma control compared with patients continuing usual care.

British drugmaker GlaxoSmithKline, on Tuesday, agreed to buy Aiolos Bio for up to $1.4 billion (R33.6bn), with focus on an asthma medication still at the testing stage. The acquisition hands GSK ...

Pharmaceutical giant GSK has struck a deal worth up to 1.4 billion US dollars (£1.1 billion) to buy asthma drug firm Aiolos Bio. The takeover of the three-month-old start-up is part of GSK’s ...